Mesothelium Guardian | Protect Mesothelioma

Malignant Peritoneal Mesothelioma is neoplasm arising from the serosal lining of the peritoneal and pericardial cavities. Primary tumors arising from the peritoneal mesothelioma are extremely rare. The accurate diagnosis of the diffuse peritoneal mesothelioma is important because it almost invariably has a fatal outcome. In many cases, malignant peritoneal mesothelioma is not diagnosed until after surgery or autopsy. The distinction of the malignant peritoneal mesothelioma from tumors metastatic to the serosal membranes can often be made based on the results of histochemical studies.

The most common symptoms of malignant peritoneal mesothelioma are difficulty in breathing, chest pain, or both. Other symptoms include weight loss, fever, night sweats, cough, and a general feeling of not being well, although these symptoms are not as common.
The standard treatment for the malignant peritoneal mesothelioma is not curative. Aggressive treatment will enable some patients to experience long-term survival, but it is still unclear whether overall survival rates would be significantly changed by different treatments or combinations of treatments.

There are different treatments available for the malignant peritoneal mesothelioma, depending upon the state of its diagnosis. For stage one, that is localized malignant peritoneal Mesothelioma, standard treatments are malignant peritoneal mesothelioma, intracavitary mesothelioma, intracavitary chemotherapy following resection.
For stages 2 to 4, that is advanced malignant peritoneal mesothelioma, treatments available are symptomatic treatment to include drainage of effusions, chest tube pleurodesis, or thoracoscopic pleurodesis, palliative surgical resection in selected patients, palliative radiation therapy, single-agent chemotherapy, and multimodality clinical trials